»ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå ±Ô¸ð´Â ¾ÕÀ¸·Î ¼ö³â°£ °·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡´Â CAGR 6.7%·Î 9¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø±â°£ÀÇ ¼ºÀåÀº ÇコÄɾî Àü¹®°¡³ª ÀϹÝÁÖ¹ÎÀÇ »ïÂ÷ ½Å°æÅë¿¡ ´ëÇÑ ÀÎÁöµµÀÇ Çâ»ó, TN»ç·Ê Áõ°¡, ³ëÀÎ Áõ°¡, ÀÇ·áºñ Áõ°¡, Áø´Ü»ç·Ê ¼ö Áõ°¡ µî¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ½Å°æÁ¶Àý ±â¼úÀÇ Áøº¸, Á¶»ç ±â¼úÀÇ Çâ»ó, ÀÇ·á ¿¬±¸¿Í ±â¼úÀÇ Áøº¸, Àúħ½À ¼ö¼ú ±â¼úÀÇ Ã¤ÅÃ, µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.
½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¾ÕÀ¸·Î ¼ö ³â°£ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Å°æ Áúȯ¿¡´Â ³ú, ô¼ö, ½Å°æÀ» Æ÷ÇÔÇÑ ½Å°æ°è¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁúȯÀÌ Æ÷ÇԵ˴ϴÙ. À¯ÀüÀû ¼ÒÀÎ, °¨¿°, ¿Ü»ó, µ¶¼Ò, ÀÚ°¡¸é¿ª ¹ÝÀÀ, º¯¼º µî ´Ù¾çÇÑ ¿äÀεéÀÌ ÀÌ·¯ÇÑ Áúº´ÀÇ À¯º´·ü »ó½Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. »ïÂ÷ ½Å°æÅë Ä¡·á´Â ½ÉÇÑ ¾È¸é ÅëÁõ ¿ÏÈ, ½Å°æ ÀÚ±Ø ¿ÏÈ, QOL Çâ»ó, ÅëÁõ °ü¸®, Ãß°¡ ½Å°æ Àå¾Ö ¿¹¹æÀ» ÅëÇØ ½Å°æ Áúȯ ȯÀÚ¸¦ Áö¿øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù º§±â¿¡¿¡ ±â¹ÝÀ» µÐ ºñ¿µ¸® ´ÜüÀÎ European Brain CouncilÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, 600°³ ÀÌ»óÀÇ ½Å°æÁúȯ°ú 300°³ÀÇ Á¤½ÅÁúȯÀÌ Àü ¼¼°è ¼ö¹é¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç 6,500¸¸ ¸íÀÇ °£ÁúȯÀÚ°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. À¯·´¸¸À¸·Îµµ 1,050¸¸¸íÀÌ Ä¡¸ÅÀ̸ç, 2050³â¿¡´Â 1,870¸¸¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú, ½Å°æÁúȯÀÇ ÀÌȯÀ² Áõ°¡°¡ »ïÂ÷ ½Å°æÅë Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
»ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä±â¾÷Àº ±ÔÁ¦´ç±¹ÀÇ ½ÂÀÎÀ» ¹Þ¾Æ ½ÃÀå¿¡¼ÀÇ Á¸À縦 È®´ëÇϱâ À§ÇØ ½ÃÇè¿ë ½Å¾à(IND) ½Åû¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.
IND ½ÅûÀ» ÅëÇØ Á¦¾à ȸ»ç´Â ±ÔÁ¦ ´ç±¹¿¡ ½ÂÀÎÀ» ¿äûÇÏ¿© ÀÎü ÀÓ»ó °Ë»ç¸¦ ½ÃÀÛÇϰí ÀǾàǰÀÇ ¾ÈÀü¼º, È¿´É ¹× ÀûÀýÇÑ º¹¿ë·®À» Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ½ºÀ§½º¿¡ ±â¹ÝÀ» µÐ ÀÓ»ó ´Ü°èÀÇ »ý¸í °øÇÐ ±â¾÷ÀÎ Noema Pharma´Â 2022³â 2¿ù, »ïÂ÷ ½Å°æÅë(TN)À» ´ë»óÀ¸·Î mGluR5 ¾ïÁ¦Á¦ NOE-101ÀÇ 2b»ó ÀÓ»ó °Ë»ç¸¦ ½ÃÀÛÇϱâ À§ÇÑ IND ½ÂÀÎÀ» ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ ÃëµæÇß½À´Ï´Ù. LibraTN ¿¬±¸´Â ¼ºÀÎÀÇ »ïÂ÷ ½Å°æÅë(TN) °ü·Ã ÅëÁõ¿¡ ´ëÇÑ NOE-101ÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» Æò°¡ÇÏ´Â 24ÁÖ°£ÀÇ ´Ù±â°ü, À§¾à ´ëÁ¶ ÀÓ»ó½ÃÇèÀ̸ç, 2024³â »ó¹Ý±â¿¡ °á°ú°¡ ³ª¿Ã ¿¹Á¤ÀÔ´Ï´Ù. ¶ÇÇÑ FDA´Â ¹Ù½É ±Û·ç¶õÆ®(NOE-101)ÀÇ °³¹ß°ú ¾à»ç ½É»ç ÇÁ·Î¼¼½º¸¦ °¡¼ÓÈÇϱâ À§ÇØ ÆÐ½ºÆ® Æ®·¢ ÁöÁ¤À» ½Ç½ÃÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå Æ¯Â¡
Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«
Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À
Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á PESTEL ºÐ¼®(Á¤Ä¡, »çȸ, ±â¼ú, ȯ°æ, ¹ýÀû ¿äÀÎ, ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ)
- ÃÖÁ¾ ÀÌ¿ë »ê¾÷ÀÇ ºÐ¼®
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : ¼ºÀå·ü ºÐ¼®
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå ½ÇÀû : ±Ô¸ð¿Í ¼ºÀå, 2019-2024³â
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå ¿¹Ãø : ±Ô¸ð¿Í ¼ºÀå, 2024-2029³â, 2034³â
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á Àüü ½ÃÀå ±Ô¸ð(TAM)
Á¦6Àå ½ÃÀå ¼¼ºÐÈ
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ÀǾàǰ
- ¼ö¼ú
- ±âŸ Ä¡·á À¯Çü
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : À¯Åë ä³Îº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- º´¿ø
- Àü¹® Ŭ¸®´Ð
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- ±âŸ
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : ÀǾàǰº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- Ç×°æ·ÃÁ¦
- ±ÙÀ° ÀÌ¿ÏÁ¦
- Ç׿ì¿ïÁ¦
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : ¼ö¼úº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ¹Ì¼¼ Ç÷°ü °¨¾Ð ¼ö¼ú
- °¨¸¶³ªÀÌÇÁ ¹æ»ç¼± ¼ö¼ú
- »Ñ¸® Àý´Ü¼ú
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : ±âŸ Ä¡·á À¯Çüº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ½Å°æ ºí·Ï
- Á¤À§ ¹æ»ç¼± ¼ö¼ú
- ¹°¸®Ä¡·á
Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : Áö¿ªº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ¼¼°èÀÇ »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : ±¹°¡º°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
Á¦9Àå Áß±¹ ½ÃÀå
Á¦10Àå Àεµ ½ÃÀå
Á¦11Àå ÀϺ» ½ÃÀå
Á¦12Àå È£ÁÖ ½ÃÀå
Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå
Á¦14Àå Çѱ¹ ½ÃÀå
Á¦15Àå ¼À¯·´ ½ÃÀå
Á¦16Àå ¿µ±¹ ½ÃÀå
Á¦17Àå µ¶ÀÏ ½ÃÀå
Á¦18Àå ÇÁ¶û½º ½ÃÀå
Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå
Á¦20Àå ½ºÆäÀÎ ½ÃÀå
Á¦21Àå µ¿À¯·´ ½ÃÀå
Á¦22Àå ·¯½Ã¾Æ ½ÃÀå
Á¦23Àå ºÏ¹Ì ½ÃÀå
Á¦24Àå ¹Ì±¹ ½ÃÀå
Á¦25Àå ij³ª´Ù ½ÃÀå
Á¦26Àå ³²¹Ì ½ÃÀå
Á¦27Àå ºê¶óÁú ½ÃÀå
Á¦28Àå Áßµ¿ ½ÃÀå
Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå
Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ
- »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : °æÀï ±¸µµ
- »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå : ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Aetna Inc.
- Thermo Fisher Scientific Inc.
- Novartis AG
- Sandoz
- Sun Pharmaceutical Industries Ltd.
Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷
- Apotex Inc.
- Lupin Limited
- Taro Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Kriya Therapeutics
- Convergence Pharmaceuticals Limited
- Noema Pharma AG
- Max Healthcare
- Initiator Pharma AS
- Coda BIoTherapeutics Inc.
- Oxford Cannabinoid Technologies Holdings Plc
- NanoVibronix
- Biogen Idec
- Shanghai SIMR BIoTechnology Co. Ltd.
- Capnia Inc.
Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå
Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)
Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ
Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«
- »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå, 2029³â : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ±¹°¡
- »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå, 2029³â : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ºÎ¹®
- »ïÂ÷ ½Å°æÅë Ä¡·á ½ÃÀå, 2029³â : ¼ºÀå Àü·«
- ½ÃÀå µ¿Çâ¿¡ ÀÇÇÑ Àü·«
- °æÀï Àü·«
Á¦36Àå ºÎ·Ï
SHW
Trigeminal neuralgia treatment involves medical strategies to manage the severe, sharp facial pain caused by trigeminal neuralgia, which affects the trigeminal nerve. The primary goal of treatment is to alleviate pain, reduce the frequency and intensity of episodes, and address underlying nerve irritation, ultimately improving the patient's quality of life.
The main types of trigeminal neuralgia treatment include medications, surgery, and other therapeutic approaches. Medications are formulated to reduce pain by controlling nerve activity. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by several end-users, such as hospitals, specialty clinics, and ambulatory surgical centers.
The trigeminal neuralgia treatment market research report is one of a series of new reports from The Business Research Company that provides trigeminal neuralgia treatment market statistics, including the trigeminal neuralgia treatment industry global market size, regional shares, competitors with the trigeminal neuralgia treatment market share, detailed trigeminal neuralgia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the trigeminal neuralgia treatment industry. This trigeminal neuralgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The trigeminal neuralgia treatment market size has grown strongly in recent years. It will grow from $0.68 billion in 2024 to $0.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the increasing incidence of chronic diseases, the rising prevalence of neurological disorders and trigeminal neuralgia, the growing demand for minimally invasive treatments, and the increasing preference for minimally invasive surgeries.
The trigeminal neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing awareness of trigeminal neuralgia among healthcare professionals and the general population, a rise in TN cases, a growing geriatric population, increasing healthcare expenditure, and a higher number of diagnosed cases. Major trends include advancements in neuromodulation techniques, improvements in TENS technology, progress in medical research and technology, the adoption of minimally invasive surgical techniques, and the integration of digital health technologies.
The increasing prevalence of neurological disorders is expected to drive the expansion of the trigeminal neuralgia treatment market in the coming years. Neurological disorders encompass conditions that affect the nervous system, including the brain, spinal cord, and nerves. Various factors contribute to the rising prevalence of these disorders, such as genetic predisposition, infections, trauma, toxins, autoimmune responses, and degeneration. Trigeminal neuralgia treatment helps neurological patients by alleviating severe facial pain, reducing nerve irritation, improving quality of life, managing pain, and preventing further neurological damage. For example, in April 2022, data from the European Brain Council, a Belgium-based non-profit organization, indicated that more than 600 neurological diseases and nearly 300 psychiatric conditions impact millions worldwide, including 65 million people with epilepsy. In Europe alone, 10.5 million individuals have dementia, with projections estimating an increase to 18.7 million by 2050. Consequently, the growing incidence of neurological disorders is expected to fuel the demand for trigeminal neuralgia treatments.
Leading companies in the trigeminal neuralgia treatment market are focusing on investigational new drug (IND) applications to obtain regulatory approvals and expand their market presence. An IND application allows pharmaceutical companies to seek approval from regulatory agencies to begin human clinical trials, assessing a drug's safety, efficacy, and appropriate dosage. For instance, in February 2022, Noema Pharma, a Switzerland-based clinical-stage biotechnology company, received IND approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b clinical trial for the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN). The LibraTN study is a 24-week, multi-center, placebo-controlled trial evaluating the efficacy and safety of NOE-101 in adults experiencing TN-related pain, with results expected in the first half of 2024. Additionally, the FDA granted fast track designation to basimglurant (NOE-101) to accelerate its development and regulatory review process.
In October 2022, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Biohaven Pharmaceuticals for approximately $11.6 billion. This acquisition aims to strengthen Pfizer's neurology portfolio by securing full rights to Biohaven Pharmaceuticals' migraine treatments, including Nurtec ODT (rimegepant) and other CGRP receptor antagonists. The deal enhances Pfizer's leadership in the migraine treatment market while expanding its pipeline of innovative neurological therapies. Biohaven Pharmaceuticals, a U.S.-based pharmaceutical company, has also been involved in researching and developing potential treatments for trigeminal neuralgia, including rimegepant.
Major players in the trigeminal neuralgia treatment market are Aetna Inc., Thermo Fisher Scientific Inc., Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Initiator Pharma AS, Coda Biotherapeutics Inc., Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Biogen Idec, Shanghai SIMR Biotechnology Co. Ltd., Capnia Inc.
North America was the largest region in the trigeminal neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the trigeminal neuralgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The trigeminal neuralgia treatment market consists of revenues earned by entities by providing services such as physical therapy, patient education, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The trigeminal neuralgia treatment market also includes sales of anticonvulsants, muscle relaxants, and tricyclic antidepressants (TCAs). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Trigeminal Neuralgia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on trigeminal neuralgia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for trigeminal neuralgia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The trigeminal neuralgia treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Medications; Surgery; Other Treatment Types
- 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
- Subsegments:
- 1) By Medications: Anticonvulsants; Muscle Relaxants; Antidepressants
- 2) By Surgery: Microvascular Decompression Surgery; Gamma Knife Radiosurgery; Rhizotomy
- 3) By Other Treatment Types: Nerve Blocks; Stereotactic Radiosurgery; Physical Therapy
- Companies Mentioned: Aetna Inc.; Thermo Fisher Scientific Inc.; Novartis AG; Sandoz; Sun Pharmaceutical Industries Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Trigeminal Neuralgia Treatment Market Characteristics
3. Trigeminal Neuralgia Treatment Market Trends And Strategies
4. Trigeminal Neuralgia Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Trigeminal Neuralgia Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Trigeminal Neuralgia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Trigeminal Neuralgia Treatment Market Growth Rate Analysis
- 5.4. Global Trigeminal Neuralgia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Trigeminal Neuralgia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Trigeminal Neuralgia Treatment Total Addressable Market (TAM)
6. Trigeminal Neuralgia Treatment Market Segmentation
- 6.1. Global Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medications
- Surgery
- Other Treatment Types
- 6.2. Global Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.3. Global Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Other End-Users
- 6.4. Global Trigeminal Neuralgia Treatment Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anticonvulsants
- Muscle Relaxants
- Antidepressants
- 6.5. Global Trigeminal Neuralgia Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Microvascular Decompression Surgery
- Gamma Knife Radiosurgery
- Rhizotomy
- 6.6. Global Trigeminal Neuralgia Treatment Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nerve Blocks
- Stereotactic Radiosurgery
- Physical Therapy
7. Trigeminal Neuralgia Treatment Market Regional And Country Analysis
- 7.1. Global Trigeminal Neuralgia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Trigeminal Neuralgia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Trigeminal Neuralgia Treatment Market
- 8.1. Asia-Pacific Trigeminal Neuralgia Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Trigeminal Neuralgia Treatment Market
- 9.1. China Trigeminal Neuralgia Treatment Market Overview
- 9.2. China Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Trigeminal Neuralgia Treatment Market
- 10.1. India Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Trigeminal Neuralgia Treatment Market
- 11.1. Japan Trigeminal Neuralgia Treatment Market Overview
- 11.2. Japan Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Trigeminal Neuralgia Treatment Market
- 12.1. Australia Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Trigeminal Neuralgia Treatment Market
- 13.1. Indonesia Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Trigeminal Neuralgia Treatment Market
- 14.1. South Korea Trigeminal Neuralgia Treatment Market Overview
- 14.2. South Korea Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Trigeminal Neuralgia Treatment Market
- 15.1. Western Europe Trigeminal Neuralgia Treatment Market Overview
- 15.2. Western Europe Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Trigeminal Neuralgia Treatment Market
- 16.1. UK Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Trigeminal Neuralgia Treatment Market
- 17.1. Germany Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Trigeminal Neuralgia Treatment Market
- 18.1. France Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Trigeminal Neuralgia Treatment Market
- 19.1. Italy Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Trigeminal Neuralgia Treatment Market
- 20.1. Spain Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Trigeminal Neuralgia Treatment Market
- 21.1. Eastern Europe Trigeminal Neuralgia Treatment Market Overview
- 21.2. Eastern Europe Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Trigeminal Neuralgia Treatment Market
- 22.1. Russia Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Trigeminal Neuralgia Treatment Market
- 23.1. North America Trigeminal Neuralgia Treatment Market Overview
- 23.2. North America Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Trigeminal Neuralgia Treatment Market
- 24.1. USA Trigeminal Neuralgia Treatment Market Overview
- 24.2. USA Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Trigeminal Neuralgia Treatment Market
- 25.1. Canada Trigeminal Neuralgia Treatment Market Overview
- 25.2. Canada Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Trigeminal Neuralgia Treatment Market
- 26.1. South America Trigeminal Neuralgia Treatment Market Overview
- 26.2. South America Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Trigeminal Neuralgia Treatment Market
- 27.1. Brazil Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Trigeminal Neuralgia Treatment Market
- 28.1. Middle East Trigeminal Neuralgia Treatment Market Overview
- 28.2. Middle East Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Trigeminal Neuralgia Treatment Market
- 29.1. Africa Trigeminal Neuralgia Treatment Market Overview
- 29.2. Africa Trigeminal Neuralgia Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Trigeminal Neuralgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Trigeminal Neuralgia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Trigeminal Neuralgia Treatment Market Competitive Landscape And Company Profiles
- 30.1. Trigeminal Neuralgia Treatment Market Competitive Landscape
- 30.2. Trigeminal Neuralgia Treatment Market Company Profiles
- 30.2.1. Aetna Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sandoz Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
31. Trigeminal Neuralgia Treatment Market Other Major And Innovative Companies
- 31.1. Apotex Inc.
- 31.2. Lupin Limited
- 31.3. Taro Pharmaceutical Industries Ltd.
- 31.4. Torrent Pharmaceuticals Ltd.
- 31.5. Kriya Therapeutics
- 31.6. Convergence Pharmaceuticals Limited
- 31.7. Noema Pharma AG
- 31.8. Max Healthcare
- 31.9. Initiator Pharma AS
- 31.10. Coda Biotherapeutics Inc.
- 31.11. Oxford Cannabinoid Technologies Holdings Plc
- 31.12. NanoVibronix
- 31.13. Biogen Idec
- 31.14. Shanghai SIMR Biotechnology Co. Ltd.
- 31.15. Capnia Inc.
32. Global Trigeminal Neuralgia Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Trigeminal Neuralgia Treatment Market
34. Recent Developments In The Trigeminal Neuralgia Treatment Market
35. Trigeminal Neuralgia Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Trigeminal Neuralgia Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Trigeminal Neuralgia Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Trigeminal Neuralgia Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer